Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b: Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-α-2b in patients with metastatic renal cell carcinoma

Nizar M. Tannir, Lorenzo Cohen, Xuemei Wang, Peter Thall, Paul F. Mathew, Eric Jonasch, Arlene Siefker-Radtke, Lance C. Pagliaro, Chaan S. Ng, Christopher Logothetis

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b: Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-α-2b in patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences